Population pharmacokinetics of levornidazole in healthy subjects and patients and sequential dosing regimen proposal using pharmacokinetic/pharmacodynamic analysis

Highlights•The first population PK model of levornidazole in Chinese subjects was developed. •PK/PD analysis of four sequential dosing regimens was performed. •Body weight was identified as a significant covariate of levornidazole clearance. •750mg q24h was proposed for patients against Bacteroides...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of antimicrobial agents Vol. 61; no. 4; p. 106754
Main Authors Cao, Yuran, Li, Yi, Guo, Beining, Zhang, Jing, Wu, Xiaojie, Yu, Jicheng, Cao, Guoying, Fan, Yaxin, Wu, Hailan
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 01.04.2023
Subjects
Aged
Anti-Bacterial Agents - pharmacology
Bacteroides
body weight
compliance
Dosing regimen
elderly
Healthy Volunteers
Humans
Infectious Disease
Levornidazole
Metabolite
metabolites
Microbial Sensitivity Tests
Monte Carlo Method
oral administration
Ornidazole - pharmacokinetics
pharmacodynamics
pharmacokinetics
PK/PD
Population pharmacokinetics
probability
PK/PD
metabolite
levornidazole
dosing regimen
population pharmacokinetics
Population pharmacokinetics
Levornidazole
Metabolite
Dosing regimen
Online AccessGet full text

Cover

More Information
Summary:Highlights•The first population PK model of levornidazole in Chinese subjects was developed. •PK/PD analysis of four sequential dosing regimens was performed. •Body weight was identified as a significant covariate of levornidazole clearance. •750mg q24h was proposed for patients against Bacteroides spp .(MIC≤1 mg/L).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0924-8579
1872-7913
1872-7913
DOI:10.1016/j.ijantimicag.2023.106754